Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
NCT04558125 · Cedars-Sinai Medical Center · PHASE4 · terminated · last registry update 2021-10-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Identification of eligible patients was slower than anticipated.” | – | Registry record, Cedars-Sinai Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-12Also stopped (terminated): Wake Forest University Health Sciences, Tenecteplase + Enoxaparin + 0.9% Saline + Enoxaparin (NCT00680628)
- 2022-08-12Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Tenecteplase (NCT05499832)
- 2022-08-02Phase 3 first posted: ZZ Biotech, LLC, 3K3A-APC (NCT05484154)
- 2022-07-19Results posted on the registry: Emory University, EACA (NCT02074436)
- 2022-07-19Also stopped (terminated): Emory University, EACA (NCT02074436)
- 2022-06-23Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Tissue Plasminogen Activator (Alteplase) (NCT05429476)
- 2022-05-27Also stopped (withdrawn): University of Alberta, Streptokinase (NCT02150785)
- 2022-05-19Also stopped (terminated): Sir Charles Gairdner Hospital, Tissue Plasminogen Activator (tPA) + recombinant deoxyribonuclease (DNase) (NCT01478698)
- 2022-03-25Phase 3 first posted: Angde Biotech Pharmaceutical Co., Ltd., Injection of recombinant human tissue plasminogen kinase derivatives + Recombinant human tissue plasminogen activator (NCT05295173)
- 2022-01-27Results posted on the registry: Denver Health and Hospital Authority, Fibrinolytic Therapy (NCT03583931)
- 2022-01-20Phase 3 first posted: Hospital Moinhos de Vento, Intravenous tenecteplase + Placebo (NCT05199662)
- 2022-01-20Phase 3 first posted: Hospital Moinhos de Vento, Tenecteplase + Placebo (NCT05199194)
- 2022-01-20Results posted on the registry: Denver Health and Hospital Authority, Alteplase 50 MG [Activase] + Alteplase 50 MG [Activase] (NCT04357730)
- 2021-12-29Also stopped (terminated): Rajaie Cardiovascular Medical and Research Center, Enoxaparin (NCT05172115)
- 2021-12-29Phase 3 first posted: Rajaie Cardiovascular Medical and Research Center, Enoxaparin (NCT05172115)
- 2021-12-02Phase 3 first posted: Beijing Tiantan Hospital, tenecteplase (0.25 mg/kg, Max 25 mg) + standard medical treatment (NCT05141305)
- 2021-11-03Phase 3 first posted: University of Melbourne, Tenecteplase + Standard Care (which may include intravenous Alteplase) (NCT05105633)
- 2021-10-25Phase 3 first posted: Assiut University, Mechanical thrombectomy + medical treatment (NCT05091320)
- 2021-09-09Also stopped (withdrawn): University of Toledo Health Science Campus, Catheter directed thrombolysis plus anticoagulation + Anticoagulation (NCT04411316)
- 2021-07-22Also stopped (withdrawn): Second Affiliated Hospital, Zhejiang University, School of Medicine, Fingolimod (NCT02956200)
- 2021-07-16Phase 3 first posted: University Hospital Tuebingen, Tenecteplase (until trial protocol V04: Alteplase) (NCT04965038)
- 2021-07-13Results posted on the registry: Medical College of Wisconsin, alteplase (recombinant t-PA) + Heparin (NCT03672006)
- 2021-07-02Also stopped (terminated): Anaconda Biomed S.L., a drug against PLAT (NCT04095767)
- 2021-06-11Also stopped (terminated): Victor Tapson, MD, Alteplase + Unfractionated heparin (NCT03988842)
- 2021-06-07Phase 3 first posted: Boehringer Ingelheim, tenecteplase + alteplase (NCT04915729)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision